Andra AP fonden Has $28.34 Million Stock Holdings in Cencora, Inc. (NYSE:COR)

Andra AP fonden raised its stake in Cencora, Inc. (NYSE:COR) by 11.5% during the 2nd quarter, Holdings Channel.com reports. The firm owned 125,800 shares of the company’s stock after buying an additional 13,000 shares during the period. Andra AP fonden’s holdings in Cencora were worth $28,343,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of the stock. Vanguard Group Inc. acquired a new stake in Cencora during the fourth quarter worth approximately $4,212,508,000. Price T Rowe Associates Inc. MD acquired a new position in Cencora in the 1st quarter valued at $2,183,619,000. JPMorgan Chase & Co. bought a new position in Cencora during the 1st quarter worth $1,199,695,000. Boston Partners acquired a new stake in shares of Cencora during the first quarter worth $1,001,269,000. Finally, Capital Research Global Investors bought a new stake in shares of Cencora in the first quarter valued at about $650,424,000. 97.52% of the stock is owned by institutional investors.

Cencora Stock Performance

NYSE COR opened at $236.53 on Tuesday. The firm’s fifty day moving average price is $232.44 and its two-hundred day moving average price is $233.20. The stock has a market cap of $46.61 billion, a PE ratio of 25.88, a PEG ratio of 1.54 and a beta of 0.44. The company has a debt-to-equity ratio of 3.93, a quick ratio of 0.55 and a current ratio of 0.89. Cencora, Inc. has a fifty-two week low of $172.41 and a fifty-two week high of $247.66.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, topping analysts’ consensus estimates of $3.18 by $0.16. The business had revenue of $74.20 billion for the quarter, compared to analyst estimates of $73.32 billion. Cencora had a return on equity of 266.60% and a net margin of 0.65%. Cencora’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.92 EPS. On average, equities analysts expect that Cencora, Inc. will post 13.61 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 9th were given a dividend of $0.51 per share. The ex-dividend date of this dividend was Friday, August 9th. This represents a $2.04 annualized dividend and a yield of 0.86%. Cencora’s dividend payout ratio is presently 22.32%.

Insiders Place Their Bets

In other news, EVP Silvana Battaglia sold 1,473 shares of the firm’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the transaction, the executive vice president now owns 10,948 shares of the company’s stock, valued at $2,656,970.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Silvana Battaglia sold 1,473 shares of the firm’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the transaction, the executive vice president now directly owns 10,948 shares of the company’s stock, valued at approximately $2,656,970.12. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the completion of the sale, the insider now owns 19,980,000 shares in the company, valued at approximately $4,806,388,800. The disclosure for this sale can be found here. Insiders have sold 4,450,399 shares of company stock valued at $1,070,392,799 in the last ninety days. 15.80% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several analysts have weighed in on COR shares. Wells Fargo & Company lifted their price objective on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 1st. JPMorgan Chase & Co. boosted their price target on Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research note on Wednesday, August 21st. Robert W. Baird cut their target price on Cencora from $287.00 to $283.00 and set an “outperform” rating for the company in a research report on Friday. StockNews.com upgraded shares of Cencora from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 2nd. Finally, Leerink Partners restated an “outperform” rating and set a $275.00 price objective on shares of Cencora in a research report on Thursday, June 27th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $258.13.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.